Hyperreflective foci (HF) are discrete, well-circumscribed
|
|
- Elfrieda Hancock
- 5 years ago
- Views:
Transcription
1 Retina Correlation Between Hyperreflective Foci and Clinical Outcomes in Neovascular Age-Related Macular Degeneration After Switching to Aflibercept Kaveh Abri Aghdam, 1,2 Amelie Pielen, 1 Carsten Framme, 1 and Bernd Junker 1 1 University Eye Hospital, Hannover Medical School, Hannover, Germany 2 Brain and Spinal Cord Injury Research Center, Neuroscience Institute, Tehran University of Medical Sciences, Tehran, Iran Correspondence: Kaveh Abri Aghdam, Medizinische Hochschule Hannover, Carl-Neuberg-Str. 1, Hannover, Germany; kaveh.abri@gmail.com. Submitted: May 25, 2015 Accepted: August 31, 2015 Citation: Abri Aghdam K, Pielen A, Framme C, Junker B. Correlation between hyperreflective foci and clinical outcomes in neovascular agerelated macular degeneration after switching to aflibercept. Invest Ophthalmol Vis Sci. 2015;56: DOI: /iovs PURPOSE. To assess the correlation between hyperreflective foci (HF) and visual and anatomical outcomes in treatment-resistant neovascular age-related macular degeneration (AMD) using spectral-domain optical coherence tomography (SD-OCT). METHODS. This was a prospective interventional case series. Thirty-three eyes of 30 consecutive patients with treatment-resistant neovascular AMD were enrolled. Intravitreal aflibercept injections were performed at week 0 (baseline), week 4, and week 8. Spectraldomain OCT images were obtained before each injection and 4 weeks after the third injection. The main focus was on the measurement of choroidal neovascularization (CNV) size in the cross-sectional area in the B-scan through the fovea, and HF number along line segments of 1- and 3-mm length passing through the fovea. RESULTS. Mean number of HF in the radius of 500 lm decreased from to (P ¼ 0.02). Mean number of HF in the radius of 1500 lm was reduced from to (P < 0.001). Mean CNV area decreased from to mm 2 (P < 0.001). There was a significant positive correlation between HF reduction in the radius of 500 lm and decrease in central subfield thickness (CST) (r ¼ 0.43, P ¼ 0.01), but no statistically significant correlation was found between HF decline in the radius of 1500 lm and other parameters. CONCLUSIONS. Switching from ranibizumab to aflibercept caused significant decrease in the number of HF 1 month after aflibercept upload, and HF decrease in the radius of 500 lm was correlated positively with the reduction in CST. Keywords: aflibercept, choroidal neovascularization, hyperreflective foci, ranibizumab, spectral domain optical coherence tomography Hyperreflective foci (HF) are discrete, well-circumscribed lesions with greater reflectivity than the retinal pigment epithelium (RPE) band on spectral-domain optical coherence tomography (SD-OCT). 1 Macular hyperpigmentation in eyes with intermediate age-related macular degeneration (AMD) has high spatial correlation to SD-OCT-detected HF and often represents the same anatomical lesion. 2 Hyperreflective foci overlying drusen are likely to represent progression of disease with RPE migration into the retina and possible photoreceptor degeneration or glial scar formation. 3 It was reported that proliferation and inner retinal migration of HF occurred during follow-up in eyes with intermediate AMD, and they were associated with higher incidence of geographic atrophy; therefore, HF proliferation and migration may serve as biomarkers for AMD progression. 4 The role of HF has been investigated in several other retinal disorders like retinitis pigmentosa, 5 central retinal vein occlusion, 6 and branch retinal vein occlusion. 7 These structures are also scattered throughout all retinal layers in diabetic macular edema (DME) and might represent the initial stages in the development of intraretinal hard exudates. 8 It has been reported that the presence of HF in the outer retina is closely related to a disrupted external limiting membrane (ELM), inner segment/outer segment (IS/ OS) line on SD-OCT images, and decreased visual acuity in DME. 9 The HF amount seems to indicate the severity of DME. Fewer HF might represent better retinal tissue integrity, whereas the presence of many HF reflects tissue disintegrity and more severe DME conditions. 10 Neovascular AMD carries a devastating visual prognosis if left untreated. 11 The use of intravitreal antivascular endothelial growth factor (VEGF) therapy is the standard of care for neovascular AMD. Intravitreal bevacizumab and ranibizumab reduce exudative fluid and improve best-corrected visual acuity (BCVA) in eyes with neovascular AMD. 12,13 However, in spite of promising results of multiple trials, many patients require continued monthly injections because of recurrent exudation, and others have an incomplete response or develop tachyphylaxis. 14 Aflibercept is a new VEGF inhibitor with a high affinity for VEGF. It is a protein manufactured by fusion of the second binding domain of the receptor VEGFR1 and the third binding domain of the receptor VEGFR2 to the crystalline portion of IgG1. 15 Intravitreal aflibercept is an effective and safe treatment for exudative AMD and not inferior to ranibizumab. 16 Patients with neovascular AMD who exhibit recurrent or resistant intraretinal or subretinal fluid following multiple injections Copyright 2015 The Association for Research in Vision and Ophthalmology, Inc. iovs.arvojournals.org j ISSN:
2 HF and AMD Outcomes After Switching to Aflibercept IOVS j October 2015 j Vol. 56 j No. 11 j 6449 FIGURE 1. Measurement of CNV size in 1:1 pixel mode using Heidelberg Eye Explorer software in the foveal section. with either bevacizumab or ranibizumab may take advantage of switching to intravitreal aflibercept therapy In this study we evaluated SD-OCT scans of eyes with treatment-resistant neovascular AMD after switching from ranibizumab to aflibercept, in order to determine the behavior of HF and their associations with visual and anatomical outcomes after three intravitreal aflibercept injections (aflibercept upload). MATERIALS AND METHODS Patient Selection Patients with treatment-resistant neovascular AMD who previously received intravitreal ranibizumab outside of the eye hospital of Hannover Medical School were assigned to aflibercept therapy in this prospective case series. The study was subject to the ethical standards stated in the 1964 Declaration of Helsinki and approved by the Clinical Research Ethics Committee of Medical School of Hannover (Medizinische Hochschule Hannover) with informed consent obtained. Treatment-resistant neovascular AMD was defined as choroidal neovascularization (CNV) secondary to AMD, which was documented in the patients records as subretinal fluid and/ or intraretinal fluid/cysts after more than 6 months of monthly ranibizumab therapy. All patients had been treated with monthly 0.5-mg ranibizumab. The interval between the last ranibizumab and the first aflibercept injection was not less than 4 or more than 6 weeks. Exclusion criteria were (1) previous macular laser photocoagulation in the study eye; (2) prior photodynamic therapy; (3) presence of fibrosis or scar in the macular region; (4) history of vitrectomy surgery; (5) history of retinal angiomatous proliferation (RAP); and (6) history of polypoidal choroidal vasculopathy (PCV) in the study eye. Each eligible eye received intravitreal injections of aflibercept at the recommended dose of 2 mg (0.05 ml) every 4 weeks for 3 months (loading phase). Comprehensive ophthalmologic examination including best-corrected visual acuity (BCVA) measurements, applanation tonometry, and ophthalmoscopy was obtained on the day of aflibercept initiation and at subsequent follow-up visits until 4 weeks after the third aflibercept injection. Image Acquisition, Processing, and Analysis Each patient underwent regular pre- and posttreatment SD- OCT (Spectralis HRAþOCT; Heidelberg Engineering, Heidelberg, Germany) examinations. The postinjection examinations were performed 4 weeks after the first injection. Spectraldomain OCT volume scans ( approximately mm) with 49 B-scans each spaced 120 lm apart and automatic real time (ART) of 16 were obtained at each session. The acquisition software version was The same horizontal B-scan sections (in x-z plane) passing through the fovea were used during the follow-up to ensure matching sections for comparison. Images were displayed using the Heidelberg Eye Explorer software version The cross-sectional CNV area in the B-scan through the fovea was measured by using the distance measurement tools in 1:1 pixel mode provided by the software (Fig. 1). In the same section of measured CNV size, evaluation of HF was performed. Hyperreflective foci were defined as focal, well-circumscribed structures with reflectivity similar to that of the RPE layer. The location of the fovea in the thickness map was used as reference point (Fig. 2). Since the central subfield thickness (CST) is defined as the average retinal thickness in the area enclosed in a 1000-lm-diameter circle centered at the center of the fovea, 20,21 two 500-lmsegment lines corresponding to the diameter of the circle were plotted from the reference point in opposite directions along the x-axis. The 1:1-lm mode was used at this stage to avoid measurement inaccuracies; then two other lines perpendicular to the aforementioned lines were drawn (Fig. 3a). Finally, measurement of the number of HF was made in the 1:1 pixel mode on a single B-scan along a line segment of length 1 mm (Fig. 3b). The magnification tool of the software was used if necessary. Using the same method, measurement of HF number was done on a single B-scan along a line segment of length 3 mm (Figs. 3c, 3d). Figure 4 shows labeled examples of dots counted as HF. The postoperative retinal structure was qualitatively interpreted as (1) dry, exhibiting no fluid, or (2)
3 HF and AMD Outcomes After Switching to Aflibercept IOVS j October 2015 j Vol. 56 j No. 11 j 6450 FIGURE 2. Finding the fovea in the thickness map and setting it as the reference point.
4 HF and AMD Outcomes After Switching to Aflibercept IOVS j October 2015 j Vol. 56 j No. 11 j 6451 FIGURE 3. Measurement of HF amount using Heidelberg Eye Explorer software. (a) Two 500-lm-length segment lines were plotted from the reference point in the nasal and temporal directions; then two other segment lines perpendicular to the first lines were drawn in 1:1-lm mode. (b) Counting of HF in the radius of 500 lm was performed within the surrounding area in 1:1 pixel mode. The same method was used in the radius of 1500 lm (c, d). wet, revealing unchanged edema or incomplete fluid regression. The main parameters used for quantitative evaluation of macular thickness were CST and macular volume. Statistical Analysis Data were collected and analyzed using SPSS software (version 20.0; IBM Corporation, Armonk, NY, USA). Quantitative variables were tested for normal distribution by the Kolmogorov-Smirnov test. Within-group changes from baseline were analyzed using paired t-test. Spearman rho test was used for correlation analysis. A P value of <0.05 was considered statistically significant. Means 6 standard deviation were used for reporting the results. RESULTS From June 2013 until March 2014, 40 eyes of 36 consecutive patients with treatment-resistant neovascular AMD were enrolled in this study. Seven eyes were excluded during the follow-up period: three cases due to the inappropriate picture quality and four cases of significant pigment epithelial detachment in the absence of measurable CNV. In the end, 33 eyes of 30 consecutive patients with treatment-resistant neovascular AMD were evaluated. Mean age of the patients was years (range, 56 94). Fourteen patients (46.7%) were male and 16 patients (53.3%) were female. There were 20 (60.6%) right eyes and 13 (39.4%) left eyes. Mean number of intravitreal ranibizumab injections was (range, 6 30). At baseline, mean BCVA was Early Treatment Diabetic Retinopathy Study (ETDRS) letters, and it significantly improved to ETDRS letters (P < 0.001) 1 month after the third injection. The number of HF in the radius of 500 and 1500 lm decreased 1 month after the third injection in 28 (85%) and 29 (88%) eyes, respectively. Mean number of HF in the radius of 500 lm decreased significantly from to (P ¼ 0.02). Mean number of HF in the radius of 1500 lm decreased significantly from to (P < 0.001). Mean CST
5 HF and AMD Outcomes After Switching to Aflibercept IOVS j October 2015 j Vol. 56 j No. 11 j 6452 FIGURE 4. Labeled examples of dots that are counted as HF in the radius of 500 lm (a) and 1500 lm (b). decreased from to lm (P < 0.001). Mean macular volume was mm 3 and declined to mm 3 (P < 0.001). The CNV area increased in 1 eye (3%), remained unchanged in 2 eyes (6%), and decreased in 30 eyes (90%). Mean baseline CNV area was mm 2, and it decreased significantly to mm 2 at the final visit (P < 0.001). Figure 5 shows an example of these changes. A dry macula was achieved in 21 eyes (64%), and 12 eyes (36%) showed decreased or unchanged edema. There was a weak significant positive correlation between HF reduction in the radius of 500 lm and decrease in CST (r ¼ 0.43, P ¼ 0.01), but no statistically significant correlation was found between HF decline in either the radius of 500 lm or the radius of 1500 lm, and BCVA improvement, CNV size change, and macular volume reduction. There was a positive significant correlation between baseline CST and baseline HF in the radius of 500 and 1500 lm (r ¼ 0.50, P ¼ 0.003, and r ¼ 0.35, P ¼ 0.045, respectively), but correlations between remaining baseline and final parameters were not significant. No ocular adverse effects or systemic complications occurred during the study period. DISCUSSION The RPE is characterized in vivo by its abundant melanosomes, melanolipofuscin, and lipofuscin granules, all of lysosomal lineage and all potential subcellular contributors to SD-OCT reflectivity. 22 Three RPE grades contain epithelial and nonepithelial components (sloughed, shedding, and intraretinal). Four are epithelial only (nonuniform, very nonuniform, bilaminar, and vacuolated). Two are nonepithelial only (dissociated and entombed). 23 Entombed RPE is a major finding in CNV eyes. Sloughed, dissociated, and bilaminar morphologies are other abundant RPE grades in CNV eyes. Vacuolated RPE is uncommon in CNV. According to the published histology and clinical imaging, many histologic RPE grades are transferrable to SD-OCT. Sloughed and intraretinal morphologies are excellent candidates for the subretinal and intraretinal HF repeatedly observed on SD-OCT and interpreted variably as dead RPE and melanin-containing macrophages, 24 activated RPE cells, 4 and inflammatory cells (e.g., retinal microglia). 25 Retinal pigment epithelium derived cells (subducted, melanotic, and entubulated morphologies) 26 are outside the RPE layer and not attached to a basal lamina or basal laminar deposit. Melanotic cells are exclusively found in eyes with CNV scars and defined by a variable number of very dark, spherical melanosomes of different sizes. Entubulated morphologies are detected within the lumen of outer retinal tubulation. 27 These originate mainly from sloughed RPE in intact retina peripheral to the atrophic area and account for the hyperreflective spots distinguished by SD-OCT in these formations. Hyperreflective foci migrate into inner retinal layers, and their quantity and density increase first perifoveally and then foveally in a 2-year period marked by incidence of geographic atrophy. 4
6 HF and AMD Outcomes After Switching to Aflibercept IOVS j October 2015 j Vol. 56 j No. 11 j 6453 FIGURE 5. Right eye of a 78-year-old female patient. SD-OCT represents subretinal edema and several HF in the surrounding area. CNV size is 0.63 mm 2 (a). One month after the third injection, the retina was dry and HF amount significantly decreased. CNV size was also reduced to 0.42 mm 2 (b). In the present study we measured the HF number within two regions. Since there is less retinal tissue along a line segment of length 1 mm passing through the fovea, we speculated that HF amount in the central subfield may not completely reflect their behavior; therefore, we additionally counted these foci along a line segment of length 3 mm passing through the fovea, which includes the parafoveal region. The results of this study revealed that the mean number of HF in the radius of 500 lm decreased significantly 1 month after three intravitreal aflibercept injections, and this reduction had a rather weak but significant correlation with the reduction of CST. Baseline HF number in that area was positively correlated with baseline CST and macular volume, but no correlation was found between the final number of these foci and final CST or final macular volume. The baseline HF number in the radius of 1500 lm had also a rather weak but significant correlation with baseline CST. Despite the significant reduction of HF in the radius of 1500 lm, we could not find any significant correlation with the evaluated parameters. Although the size of CNV decreased after treatment as well, no significant correlation was found between HF reduction and CNV size decline. To the best of our knowledge, this is the first study to evaluate the correlation between CNV size and HF amount in the cross-sectional OCT B-scans after switching from ranibizumab to aflibercept in patients with treatment-resistant neovascular AMD. Akagi-Kurashige and associates reported that eyes with HF at baseline had more active CNV and more severe blood retinal barrier damage. 28 A small percentage of cases without HF in their study (18.7%) had milder CNV and less
7 HF and AMD Outcomes After Switching to Aflibercept IOVS j October 2015 j Vol. 56 j No. 11 j 6454 severe blood retinal barrier damage, but they did not measure the CNV size. Initial presence of HF in the foveal neurosensory retina was associated with poor final visual acuity in their study. Framme et al. 29 studied changes in the foveal and parafoveal area before and 1 month after the third ranibizumab injection in 61 treatment-naïve eyes with neovascular AMD. The amount of small dense particles (SDPs, equivalent to HF) decreased significantly after therapy, and SDP reduction correlated weakly but positively with reduction of retinal thickness (r ¼ 0.268, P ¼ 0.040). Unlike what was seen in our study, they found a positive correlation between SDP reduction and improvement in BCVA (P ¼ 0.006). Contrary to the results of Akagi-Kurashige et al., 28 Framme et al. 29 found that the baseline amount of SDPs correlated positively with the increase in BCVA (P ¼ 0.005). They hypothesized that initial large number of HF may indicate a higher grade of inflammation, but the presence of a high number improves the effect of ranibizumab therapy in neovascular AMD, and they concluded that the amount of SDPs could be a predictive factor for the treatment outcome. Kang et al. 7 evaluated HF in 97 patients who were treated with intravitreal bevacizumab for macular edema secondary to branch retinal vein occlusion. The eyes were divided into three groups based on the location of HF on SD-OCT: HF in outer retinal layers, HF in inner retinal layers, and no HF. Final BCVA was worse in eyes with HF in the outer retinal layer group than in the other two groups (P < 0.001), although baseline BCVA was not different between them. We did not investigate the presence of HF in different retinal layers, as the small sample size after subdivision could limit the statistical analysis. The strengths of this study are its prospective design, measurement of the CNV size, and definition of the area for HF evaluation. Limitations are a relatively small sample size and effects of previous treatment with ranibizumab on the retinal structure. It would be preferable to count HF on at least three representative equally spaced line segments of 1 mm, and five such of 3 mm, so that the three segments of 1-mm length are a subset of those of 3-mm length. Furthermore, the whole size of CNV cannot be measured on a single OCT B-scan. Since almost all of the patients had been treated with ranibizumab outside of our hospital before switching to aflibercept, we encountered missing data including CST before switching to aflibercept and behavior of HF under ranibizumab therapy. Due to short follow-up duration, we did not investigate the relationship between the mentioned parameters and clinical improvement or recurrence either. The current version of Heidelberg Eye Explorer software allows calculating the area of irregularly shaped CNVs, but it is not able to detect HF automatically; therefore we counted the HF number subjectively. In summary, SD-OCT serves as a valuable tool for evaluation of changes in retinal structure during treatment and follow-up of patients with neovascular AMD. Hyperreflective foci are observed frequently in the foveal region of patients with treatment-resistant AMD. Switching from ranibizumab to aflibercept caused a predominant decrease in the number of HF within the area of 1- and 3-mm diameter 1 month after aflibercept upload. Despite the significant improvement in BCVA, reduction of CNV size, decrease in CST, and decline in macular volume, only the correlation between HF reduction in the radius of 500 lm and CST decrease was statistically significant. Further studies with a longer follow-up period are needed to evaluate the time-dependent changes. Specific software could be developed for objective assessment of HF. Acknowledgments The authors thank the German Ministry of Lower Saxony for its scientific and cultural organization to support our retinal imaging studies in the ophthalmology department of Hannover Medical School financed by Niedersachsen Vorab. Disclosure: K. Abri Aghdam, None; A. Pielen, None; C. Framme, None; B. Junker, None References 1. Ho J, Witkin AJ, Liu J, et al. Documentation of intraretinal retinal pigment epithelium migration via high-speed ultrahighresolution optical coherence tomography. Ophthalmology. 2011;118: Folgar FA, Chow JH, Farsiu S, et al. Spatial correlation between hyperpigmentary changes on color fundus photography and hyperreflective foci on SDOCT in intermediate AMD. Invest Ophthalmol Vis Sci. 2012;53: Schuman SG, Koreishi AF, Farsiu S, et al. Photoreceptor layer thinning over drusen in eyes with age-related macular degeneration imaged in vivo with spectral-domain optical coherence tomography. Ophthalmology. 2009;116: Christenbury JG, Folgar FA, O Connell RV, et al. Progression of intermediate age-related macular degeneration with proliferation and inner retinal migration of hyperreflective foci. Ophthalmology. 2013;120: Kuroda M, Hirami Y, Hata M, et al. Intraretinal hyperreflective foci on spectral-domain optical coherence tomographic images of patients with retinitis pigmentosa. Clin Ophthalmol. 2014;8: Ogino K, Murakami T, Tsujikawa A, et al. Characteristics of optical coherence tomographic hyperreflective foci in retinal vein occlusion. Retina. 2012;32: Kang JW, Lee H, Chung H, et al. Correlation between optical coherence tomographic hyperreflective foci and visual outcomes after intravitreal bevacizumab for macular edema in branch retinal vein occlusion. Graefes Arch Clin Exp Ophthalmol. 2014;252: Bolz M, Schmidt-Erfurth U, Deak G, Mylonas G, Kriechbaum K, Scholda C. Optical coherence tomographic hyperreflective foci: a morphologic sign of lipid extravasation in diabetic macular edema. Ophthalmology. 2009;116: Uji A, Murakami T, Nishijima K, et al. Association between hyperreflective foci in the outer retina, status of photoreceptor layer, and visual acuity in diabetic macular edema. Am J Ophthalmol. 2012;153: Framme C, Schweizer P, Imesch M, et al. Behavior of SD-OCTdetected hyperreflective foci in the retina of anti-vegf-treated patients with diabetic macular edema. Invest Ophthalmol Vis Sci. 2012;53: Wong T, Chakravarthy U, Klein R, et al. The natural history and prognosis of neovascular age-related macular degeneration a systematic review of the literature and meta-analysis. Ophthalmology. 2008;115: Avery RL, Pieramici DJ, Rabena MD, et al. Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Ophthalmology. 2006;113: Abraham P, Yue H, Wilson L. Randomized, double-masked, sham-controlled trial of ranibizumab for neovascular agerelated macular degeneration: PIER study year 2. Am J Ophthalmol. 2010;150: Gasperini JL, Fawzi AA, Khondkaryan A, et al. Bevacizumab and ranibizumab tachyphylaxis in the treatment of choroidal neovascularisation. Br J Ophthalmol. 2012;96: Holash J, Davis S, Papadopoulos N, et al. VEGF-Trap: a VEGF blocker with potent antitumor effects. Proc Natl Acad Sci U S A. 2002;99: Heier JS, Brown DM, Chong V, et al. Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration. Ophthalmology. 2012;119:
8 HF and AMD Outcomes After Switching to Aflibercept IOVS j October 2015 j Vol. 56 j No. 11 j Bakall B, Folk JC, Boldt HC, et al. Aflibercept therapy for exudative age-related macular degeneration resistant to bevacizumab and ranibizumab. Am J Ophthalmol. 2013;156: Ho VY, Yeh S, Olsen TW, et al. Short-term outcomes of aflibercept for neovascular age-related macular degeneration in eyes previously treated with other vascular endothelial growth factor inhibitors. Am J Ophthalmol. 2013;156: Yonekawa Y, Andreoli C, Miller JB, et al. Conversion to aflibercept for chronic refractory or recurrent neovascular agerelated macular degeneration. Am J Ophthalmol. 2013;156: Sugar EA, Jabs DA, Altaweel MM, et al. Identifying a clinically meaningful threshold for change in uveitic macular edema evaluated by optical coherence tomography. Am J Ophthalmol. 2011;152: Huang J, Liu X, Wu Z, et al. Macular thickness measurements in normal eyes with time-domain and Fourier-domain optical coherence tomography. Retina. 2009;29: Zhang QX, Lu RW, Messinger JD, Curcio CA, Guarcello V, Yao XC. In vivo optical coherence tomography of light-driven melanosome translocation in retinal pigment epithelium. Sci Rep. 2013;3: Zanzoterra EC, Messinger JD, Ach T, Smith RT, Freund KB, Curcio CA. The Project MACULA retinal pigment epithelium grading system for histology and optical coherence tomography in age-related macular degeneration. Invest Ophthalmol Vis Sci. 2015;56: Fleckenstein M, Schmitz-Valckenberg S, Adrion C, et al. Tracking progression using spectral domain optical coherence tomography in geographic atrophy due to age-related macular degeneration. Invest Ophthalmol Vis Sci. 2010;51: Leuschen JN, Schuman SG, Winter KP, et al. Spectral-domain optical coherence tomography characteristics of intermediate age-related macular degeneration. Ophthalmology. 2013;120: Zanzoterra EC, Messinger JD, Ach T, Smith RT, Curcio CA. Subducted and melanotic cells in advanced age-related macular degeneration are derived from retinal pigment epithelium. Invest Ophthalmol Vis Sci. 2015;56: Schaal KB, Freund KB, Litts KM, Zhang Y, Messinger JD, Curcio CA. Outer retinal tubulation in age-related macular degeneration: optical coherence tomographic findings correspond with histology. Retina. 2015;35: Akagi-Kurashige Y, Tsujikawa A, Oishi A, et al. Relationship between retinal morphological findings and visual function in age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol. 2012;250: Framme C, Wolf S, Wolf-Schnurrbusch U. Small dense particles in the retina observable by spectral-domain optical coherence tomography in age-related macular degeneration. Invest Ophthalmol Vis Sci. 2010;51:
Hyperreflective foci (HFs) have been frequently observed
Multidisciplinary Ophthalmic Imaging Behavior of SD-OCT Detected Hyperreflective Foci in the Retina of Anti-VEGF Treated Patients with Diabetic Macular Edema Carsten Framme, Paul Schweizer, Manfred Imesch,
More informationOptical Coherence Tomography: Pearls for the Anterior Segment Surgeon Basic Science Michael Stewart, M.D.
Optical Coherence Tomography: Pearls for the Anterior Segment Surgeon Basic Science Michael Stewart, M.D. Disclosure OCT Optical Coherence Tomography No relevant financial relationships I will refer to
More informationUse of Aflibercept in cases of recurrent or refractory neovascular AMD previously treated with other antiangiogenic drug: anatomo-functional outcomes
Use of Aflibercept in cases of recurrent or refractory neovascular AMD previously treated with other antiangiogenic drug: anatomo-functional outcomes Daniel E. Charles, MD, Martin Charles, MD, Gisela Jelusich,
More informationOptical Coherence Tomography in Diabetic Retinopathy. Mrs Samantha Mann Consultant Ophthalmologist Clinical Lead of SEL-DESP
Optical Coherence Tomography in Diabetic Retinopathy Mrs Samantha Mann Consultant Ophthalmologist Clinical Lead of SEL-DESP Content OCT imaging Retinal layers OCT features in Diabetes Some NON DR features
More informationEfficacy of Anti-VEGF Agents in the Treatment of Age-Related Macular Degeneration
Efficacy of Anti-VEGF Agents in the Treatment of Age-Related Macular Degeneration Marilita M. Moschos Abstract- Purpose: To evaluate by OCT and mf-erg the macular function in eyes with CNV due to ARMD
More informationShort-term outcomes of switching anti-vegf agents in eyes with treatment-resistant wet AMD
Batioglu et al. BMC Ophthalmology (2015) 15:40 DOI 10.1186/s12886-015-0025-z RESEARCH ARTICLE Open Access Short-term outcomes of switching anti-vegf agents in eyes with treatment-resistant wet AMD Figen
More informationZEISS AngioPlex OCT Angiography. Clinical Case Reports
Clinical Case Reports Proliferative Diabetic Retinopathy (PDR) Case Report 969 PROLIFERATIVE DIABETIC RETINOPATHY 1 1-year-old diabetic female presents for follow-up of proliferative diabetic retinopathy
More informationAngio-OCT. Degenerazione Maculare Legata all Eta. Giuseppe Querques
Angio-OCT Degenerazione Maculare Legata all Eta Giuseppe Querques Department of Ophthalmology, IRCCS Ospedale San Raffaele, University Vita Salute San Raffaele, Milan, Italy Financial Disclosure ADVISORY
More informationSUMMARY. Heather Casparis, MD,* and Neil M. Bressler, MD MARINA AND ANCHOR
The following are summaries of selected presentations and posters from the American Society of Retina Specialists and European VitreoRetinal Society Annual Meeting held September 9 13, 2006, in Cannes,
More informationManagement of Neovascular AMD
Kapusta AMD Part 1 Management of Neovascular AMD Dr. Michael A. Kapusta, MD, FRCSC Ophthalmologist in Chief Jewish General Hospital Vitreoretinal Surgeon 1 FINANCIAL DISCLOSURES Consulting honoraria Bayer,
More informationCENTENE PHARMACY AND THERAPEUTICS NEW DRUG REVIEW 2Q17 April May
BRAND NAME Lucentis GENERIC NAME ranibizumab MANUFACTURER Genentech, Inc. DATE OF APPROVAL June 30, 2006 PRODUCT LAUNCH DATE July 13, 2006 REVIEW TYPE Review type 1 (RT1): New Drug Review Full review of
More informationEFFICACY OF ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR AGENTS IN RETINAL DISORDER FOR BETTER VISUAL ACUITY
EFFICACY OF ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR AGENTS IN RETINAL DISORDER FOR BETTER VISUAL ACUITY Diwakar chaudhary *1, 2, Hu shuqiong, Long Yuan and Xiong kun 1 Yangtze University, 1 Nanhuan Road
More informationOCT Angiography in Primary Eye Care
OCT Angiography in Primary Eye Care An Image Interpretation Primer Julie Rodman, OD, MS, FAAO and Nadia Waheed, MD, MPH Table of Contents Diabetic Retinopathy 3-6 Choroidal Neovascularization 7-9 Central
More informationAge-related macular degeneration (AMD) is one of the leading
Retina Quantification of the Therapeutic Response of Intraretinal, Subretinal, and Subpigment Epithelial Compartments in Exudative AMD during Anti-VEGF Therapy Isabelle Golbaz, Christian Ahlers, Geraldine
More informationRetinal Pigment Epithelial Tears (Rips) in the ERA of Anti Vegf - When and Why?
Original Article Retinal Pigment Epithelial Tears (Rips) in the ERA of Anti Vegf - When and Why? Dr Sreelekha S. MS, DNB, DO, FRCS, Dr Manoj Soman DNB, FICO, FRCS, Dr. Unni Nair MS, FRCS, Dr. Ruminder
More informationAcquired vitelliform detachment in patients with subretinal drusenoid deposits (reticular pseudodrusen)
Zurich Open Repository and Archive University of Zurich Main Library Strickhofstrasse 39 CH-8057 Zurich www.zora.uzh.ch Year: 2011 Acquired vitelliform detachment in patients with subretinal drusenoid
More informationClinical Trial Endpoints for Macular Diseases
Clinical Trial Endpoints for Macular Diseases Developed in collaboration Learning Objective Upon completion, participants should be able to: Summarize types of biomarkers of progression and treatment response
More informationOpthea Initiates OPT-302 Diabetic Macular Edema Clinical Trial
ASX and Media Release 3 January 2018 Opthea Initiates OPT-302 Diabetic Macular Edema Clinical Trial Melbourne, Australia; January 3 2018 Opthea Limited (ASX:OPT), a late stage biopharmaceutical company
More informationDiabetic Macular Edema Treatment in the 21st Century
Transcript Details This is a transcript of a continuing medical education (CME) activity accessible on the ReachMD network. Additional media formats for the activity and full activity details (including
More informationClinical Study Switch to Aflibercept in Diabetic Macular Edema Patients Unresponsive to Previous Anti-VEGF Therapy
Hindawi Ophthalmology Volume 2017, Article ID 5632634, 4 pages https://doi.org/10.1155/2017/5632634 Clinical Study Switch to Aflibercept in Diabetic Macular Edema Patients Unresponsive to Previous Anti-VEGF
More informationNIH Public Access Author Manuscript JAMA Ophthalmol. Author manuscript; available in PMC 2013 September 10.
NIH Public Access Author Manuscript Published in final edited form as: JAMA Ophthalmol. 2013 May ; 131(5): 693 694. doi:10.1001/jamaophthalmol.2013.692. Effect of Intravitreous Anti Vascular Endothelial
More informationPersistent Macular Thickening After Ranibizumab Treatment for Diabetic Macular Edema With Vision Impairment
9:30 AM Persistent Macular Thickening After Ranibizumab Treatment for Diabetic Macular Edema With Vision Impairment Lee Jampol, MD OBJECTIVE To assess subsequent visual and anatomic outcomes of eyes with
More informationHHS Public Access Author manuscript Ophthalmic Surg Lasers Imaging Retina. Author manuscript; available in PMC 2016 January 14.
High-Speed Ultrahigh-Resolution OCT of Bruch s Membrane in Membranoproliferative Glomerulonephritis Type 2 Mehreen Adhi, MD, Sarah P. Read, MD, PhD, Jonathan J. Liu, PhD, James G. Fujimoto, PhD, and Jay
More informationLong-term Management of AMD. Motasem Al-latayfeh, MD Assistant Prof. Ophthalmology Hashemite University Jordan
Long-term Management of AMD Motasem Al-latayfeh, MD Assistant Prof. Ophthalmology Hashemite University Jordan DEFINITION 1 Age-related macular degeneration (AMD) is a disorder of the macula characterized
More informationA Treat and Extend Regimen Using Ranibizumab for Neovascular Age-Related Macular Degeneration
A Treat and Extend Regimen Using Ranibizumab for Neovascular Age-Related Macular Degeneration Clinical and Economic Impact Omesh P. Gupta, MD, MBA, Gary Shienbaum, MD, Avni H. Patel, MD, Christopher Fecarotta,
More informationOishi A, Miyamoto K, Yoshimura N. Etiology of carotid cavernous fistula in Japanese. Jpn J Ophthalmol. 2009;53:40-43.
Kimura T, Takagi H, Miyamoto K, Kita M, Watanabe D, Yoshimura N. Macular hole with epiretinal membrane after triamcinolone-assisted vitrectomy for proliferative diabetic retinopathy. Retinal Cases Brief
More informationCitation. As Published Publisher. Version
Effect of Intravitreous Anti Vascular Endothelial Growth Factor Therapy on Choroidal Thickness in Neovascular Age-Related Macular Degeneration Using Spectral-Domain The MIT Faculty has made this article
More informationInternational Journal of Health Sciences and Research ISSN:
International Journal of Health Sciences and Research www.ijhsr.org ISSN: 2249-9571 Original Research Article A Multivariate Analysis of Intravitreal Injection of Anti-VEGF Bevacizumab in the Treatment
More informationClinical results of OPT-302 (VEGF-C/D Trap ) Combination Treatment in namd and DME
Clinical results of OPT-302 (VEGF-C/D Trap ) Combination Treatment in namd and DME Ophthalmology Innovation Summit @ AAO, October 25 2018 Megan Baldwin PhD, CEO & Managing Director Disclaimer Investment
More informationMONTHLY ADMINISTERED INTRAVITREOUS PHARmacotherapy
Polypoidal Choroidal Vasculopathy Masquerading as Neovascular Age-Related Macular Degeneration Refractory to Ranibizumab ALEXANDROS N. STANGOS, JAGDEEP SINGH GANDHI, JAYASHREE NAIR-SAHNI, HEINRICH HEIMANN,
More informationClinical results of OPT-302 (VEGF-C/D Trap ) Combination Treatment in namd and DME
Clinical results of OPT-302 (VEGF-C/D Trap ) Combination Treatment in namd and DME Ophthalmology Innovation Summit @ AAO, October 25 2018 Megan Baldwin PhD, CEO & Managing Director Disclaimer Investment
More informationOptical Coherence Tomography (OCT) in Uveitis Piergiorgio Neri, BMedSc, MD, PhD Head Ocular Immunology Unit
The Eye Clinic Polytechnic University of Marche Head: Prof Alfonso Giovannini November, 1991 Optical Coherence Tomography (OCT) in Uveitis Piergiorgio Neri, BMedSc, MD, PhD Head Ocular Immunology Unit
More informationAge-related macular degeneration (AMD) is the leading cause
Special Issue Changes in Neovascular Lesion Hyperreflectivity After Anti-VEGF Treatment in Age-Related Macular Degeneration: An Integrated Multimodal Imaging Analysis Giuseppe Casalino, 1,2 Francesco Bandello,
More informationLondon Medicines Evaluation Network Review
London Medicines Evaluation Network Review Evidence for initiating intravitreal bevacizumab for the management of wet age-related macular degeneration (wet-amd) in eyes with vision better than 6/12 November
More informationA Comparative Study of Age Related Macular Degeneration In Relation To SD-OCTand Fundus Photography.
IOSR Journal of Dental and Medical Sciences (IOSR-JDMS) e-issn: 2279-0853, p-issn: 2279-0861.Volume 14, Issue 11 Ver. III (Nov. 2015), PP 33-37 www.iosrjournals.org A Comparative Study of Age Related Macular
More informationP. Stavrakas MD PhD. Consultant Ophthalmologist and vitreoretinal surgeon 2 nd Department of Ophthalmology University of Athens
P. Stavrakas MD PhD Consultant Ophthalmologist and vitreoretinal surgeon 2 nd Department of Ophthalmology University of Athens Primary diagnose of exudative AMD Anti-VEGF monotherapy treatment Loss of
More informationHyungwoo Lee, Hyoik Jang, Youn A Choi, Hyung Chan Kim, and Hyewon Chung
Retina Association Between Soluble CD14 in the Aqueous Humor and Hyperreflective Foci on Optical Coherence Tomography in Patients With Diabetic Macular Edema Hyungwoo Lee, Hyoik Jang, Youn A Choi, Hyung
More informationCitation BioMed Research International, 2015, v. 2015, article no Creative Commons: Attribution 3.0 Hong Kong License
Title Relationship between Outer Retinal Layers Thickness and Visual Acuity in Diabetic Macular Edema Author(s) Wong, RLM; Lee, JWY; Yau, GSK; Wong, IYH Citation BioMed Research International, 2015, v.
More informationEllabban, Abdallah A; Yoshimura, Na.
Association between hyperreflective Titlestatus of photoreceptor layer, and macular edema. Uji, Akihito; Murakami, Tomoaki; Ni Author(s) Tadamichi; Horii, Takahiro; Arakawa Ellabban, Abdallah A; Yoshimura,
More informationMacular Morphology and Visual Acuity in the Comparison of Age-related Macular Degeneration Treatments Trials
Macular Morphology and Visual Acuity in the Comparison of Age-related Macular Degeneration Treatments Trials Glenn J. Jaffe, MD, 1 Daniel F. Martin, MD, 2 Cynthia A. Toth, MD, 1 Ebenezer Daniel, MPH, PhD,
More informationIntraocular Radiation Therapy for Age-Related Macular Degeneration
Medical Policy Manual Medicine, Policy No. 134 Intraocular Radiation Therapy for Age-Related Macular Degeneration Next Review: April 2019 Last Review: June 2018 Effective: August 1, 2018 IMPORTANT REMINDER
More informationThe Quick Guide to OCT Mastery 50 Real Cases with Expert Analysis
OPTICAL COHERENCE TOMOGRAPHY The Quick Guide to OCT Mastery 50 Real Cases with Expert Analysis VOL 1 Sanjay Sharma, MD, FRCS, MSc (Epid), MBA Ophthalmologist, Epidemiologist Queen s University, Canada
More informationClinical Trials Related to Age Related Macular Degeneration
Clinical Trials Related to Age Related Macular Degeneration Kirti Singh MD, DNB, FRCS Kirti Singh MD, DNB, FRCS, Pooja Jain MBBS, Nitasha Ahir MBBS, Divya Jain MD, DNB Guru Nanak Eye Centre, Maulana Azad
More informationDiagnosis and treatment of diabetic retinopathy. Blake Cooper MD Ophthalmologist Vitreoretinal Surgeon Retina Associates Kansas City
Diagnosis and treatment of diabetic retinopathy Blake Cooper MD Ophthalmologist Vitreoretinal Surgeon Retina Associates Kansas City Disclosures Consulted for Novo Nordisk 2017,2018. Will be discussing
More informationOCT Interpretation in Retinal Disease
OCT Interpretation in Retinal Disease Jay M. Haynie, OD, FAAO Financial Disclosure I have received honoraria or am on the advisory board for the following companies: Carl Zeiss Meditec Advanced Ocular
More informationNATURAL COURSE OF PATIENTS DISCONTINUING TREATMENT FOR AGE-RELATED MACULAR DEGENERATION AND FACTORS ASSOCIATED WITH VISUAL PROGNOSIS
NATURAL COURSE OF PATIENTS DISCONTINUING TREATMENT FOR AGE-RELATED MACULAR DEGENERATION AND FACTORS ASSOCIATED WITH VISUAL PROGNOSIS JAE HUI KIM, MD,* YOUNG SUK CHANG, MD, JONG WOO KIM, MD* Purpose: To
More informationAnti VEGF Agents in Retinal Disorders Current Scenario
Retina Anti VEGF Agents in Retinal Disorders Current Scenario Charu Gupta MS Charu Gupta MS, Cyrus M. Shroff MD Shroff Eye Centre, New Delhi T is a group of proteins involved in the regulation of angiogenesis,
More informationChoroidal Mapping; a Novel Approach for Evaluating Choroidal Thickness and Volume
Imaging Technique Choroidal Mapping; a Novel Approach for Evaluating Choroidal Thickness and Volume Jila Noori 1, MD; Mohammad Riazi Esfahani 1,2, MD Fedra Hajizadeh 2, MD; Mohammad-Mehdi Zaferani 1, MD
More information연령연관황반변성에서망막혈관종성증식과동반된망막색소상피박리의임상양상과일차적인광역학치료의결과
연령연관황반변성에서망막혈관종성증식과동반된망막색소상피박리의임상양상과일차적인광역학치료의결과 40 Table. Clinical characteristics and results of patients undergoing photodynamic therapy for retinal angiomatous proliferation Patients No. Age/ sex Eye
More informationClinically Significant Macular Edema (CSME)
Clinically Significant Macular Edema (CSME) 1 Clinically Significant Macular Edema (CSME) Sadrina T. Shaw OMT I Student July 26, 2014 Advisor: Dr. Uwaydat Clinically Significant Macular Edema (CSME) 2
More informationFluorescein Angiography
Last revision: October 2011 by Luis Arias Fluorescein Angiography Authors: Luis Arias, MD Hospital Universitari de Bellvitge - University of Barcelona. Spain Jordi Monés, MD Institut de la Màcula i de
More informationMacular edema (ME) is the most common
MANAGEMENT OF RETINAL VEIN OCCLUSIONS * Peter A. Campochiaro, MD ABSTRACT Macular edema (ME) is the most common cause of reduced vision in patients with retinal vein occlusions (RVOs). The primary cause
More information11/29/2016 MACULAR MALADIES: TYPICAL & ATYPICAL CASES
MACULAR MALADIES: TYPICAL & ATYPICAL CASES Dawn Pewitt, OD, FAAO Triad Eye Institute, Grove, OK Dpewitt@triadeye.com Disclosure Statement: No financial disclosures COPE 51218-PS Please silence all mobile
More informationIntraocular Radiation Therapy for Age-Related Macular Degeneration
Intraocular Radiation Therapy for Age-Related Macular Degeneration Policy Number: 9.03.20 Last Review: 9/2014 Origination: 9/2008 Next Review: 9/2015 Policy Blue Cross and Blue Shield of Kansas City (Blue
More informationOptical Coherence Tomography Monitoring Strategies for A-VEGF Treated Age-Related Macular Degeneration: An Evidence-Based Analysis
Optical Coherence Tomography Monitoring Strategies for A-VEGF Treated Age-Related Macular Degeneration: An Evidence-Based Analysis G Pron August 2014 Ontario Health Technology Assessment Series; Vol. 14:
More informationClinical Outcomes After Intravitreal Bevacizumab Injection for Diabetic Macular Edema
Original Article Clinical Outcomes After Intravitreal Bevacizumab Injection for Diabetic Macular Edema Karen Joyce G. Castro, MD, Marie Joan V. Loy, MD International Eye Institute St. Luke s Medical Center
More informationRetinal Complications of Obstructive Sleep Apnea A Growing Concern!
Retinal Complications of Obstructive Sleep Apnea A Growing Concern! Jay M. Haynie, OD, FAAO Financial Disclosure I have received honoraria or am on the advisory board for the following companies: Carl
More informationInstudies of vascular endothelial growth factor
MONITORING THERAPEUTIC EFFICACY IN THE ANTI-VEGF ERA* SriniVas R. Sadda, MD ABSTRACT One of the most important questions with vascular endothelial growth factor (VEGF) inhibitors for age-related macular
More informationOCT Assessment of the Vitreoretinal Relationship in CSME
December 2007 Sonia Rani John et al. - IFIS 375 ORIGINAL ARTICLE OCT Assessment of the Vitreoretinal Relationship in CSME Dr. Manoj S. DNB FRCS, Dr. Unnikrishnan Nair MS DO FRCS, Dr. Gargi Sathish MS Introduction
More informationSpectral-domain Optical Coherence Tomography Imaging of Age-related Macular Degeneration
Imaging Spectral-domain Optical Coherence Tomography Imaging of Age-related Macular egeneration Carlos Alexandre de Amorim Garcia Filho, 1 Philip J Rosenfeld, 2 Zohar Yehoshua 3 and Giovanni Gregori 3
More informationR&M Solutions
Mohamed Hosny El-Bradey, MD., Assistant Professor of Ophthalmology, Tanta University. Wael El Haig, MD., Professor of Ophthalmology. Zagazeeg University. 1 Myopic CNV is considered the most common vision
More informationHIGH DOSE TISSUE PLASMINOGEN ACTIVATOR (TPA) (100 MCG/0.1 ML) AND C3F8 GAS IN PNEUMATIC DISPLACEMENT OF SUBMACULAR
HIGH DOSE TISSUE PLASMINOGEN ACTIVATOR (TPA) (100 MCG/0.1 ML) AND C3F8 GAS IN PNEUMATIC DISPLACEMENT OF SUBMACULAR HAEMORRHAGE. Stephen A.M. De Souza MD, FRCSC Matthew J Welch MD, Raza M Shah MD, Alan
More informationStabilization of visual acuity with photodynamic therapy in eyes with chorioretinal anastomoses
Graefe s Arch Clin Exp Ophthalmol (2004) 242:368 376 CLINICAL INVESTIGATION DOI 10.1007/s00417-003-0844-0 Rufino M. Silva José R. Faria de Abreu António Travassos José G. Cunha-Vaz Stabilization of visual
More informationThere are no published randomized, double-blind trials comparing aflibercept to other therapies in neovascular AMD.
Subject: Eylea (aflibercept) Original Effective Date: 7/11/2014 Policy Number: MCP-191 Revision Date(s): 10/11/2016 Review Date(s): 12/16/2015; 10/11/2016, 6/22/2017, 7/10/2018 DISCLAIMER This Medical
More informationevaluation of vitreoretinal adhesions in exudative AMD using optical coherence tomography
evaluation of vitreoretinal adhesions in exudative AMD using optical coherence tomography Dr. Mahmoud Alaa Abouhusssein, FRCO Lecturer of ophthalmology, Alexandria university Dr. Amir Ramadan Gomaa, MD
More informationOptical Coherence Tomographic Reflectivity of Photoreceptors beneath Cystoid Spaces in Diabetic Macular Edema
Retina Optical Coherence Tomographic Reflectivity of Photoreceptors beneath in Diabetic Macular Edema Tomoaki Murakami, Kazuaki Nishijima, Tadamichi Akagi, Akihito Uji, Takahiro Horii, Naoko Ueda-Arakawa,
More informationIn 1990 our group first described reticular pseudodrusen as a. Choroidal Changes Associated with Reticular Pseudodrusen. Retina
Retina Choroidal Changes Associated with Reticular Pseudodrusen Giuseppe Querques, 1,2 Lea Querques, 1,2 Raimondo Forte, 1 Nathalie Massamba, 1 Florence Coscas, 1 and Eric H. Souied 1 PURPOSE. To analyze
More informationFlore De Bats, 1 Benjamin Wolff, 2,3 Martine Mauget-Faÿsse, 2 Claire Scemama, 2 and Laurent Kodjikian Introduction
Case Reports in Medicine Volume 2013, Article ID 260237, 7 pages http://dx.doi.org/10.1155/2013/260237 Case Report B-Scan and En-Face Spectral-Domain Optical Coherence Tomography Imaging for the Diagnosis
More informationDiagnosis in AMD. Managing your AMD Patients
Managing your AMD Patients Robert W. Dunphy, O.D., F.A.A.O. Diagnosis in AMD Have suspicion Identify relative risk Conduct surveillance Biometry Utilize technology to facilitate detection of change / stability
More informationThe Era of anti- - - VEGF Kirk L. Halvorson, OD
The Era of anti- - - VEGF Kirk L. Halvorson, OD Introduction: Anti- - - Vascular Endothelial Growth Factor (Anti- - - VEGF) medication is a relatively a new line of medications used in treating a variety
More informationFEP Medical Policy Manual
FEP Medical Policy Manual Last Review: September 2016 Next Review: September 2017 Related Policies 6.01.10 Stereotactic Radiosurgery and Stereotactic Body Radiotherapy 8.01.10 Charged-Particle (Proton
More informationOptimizing the Anti-VEGF Treatment Strategy for Neovascular Age-Related Macular Degeneration: From Clinical Trials to Real-Life Requirements
Perspective DOI: 10.1167/tvst.4.3.6 Optimizing the Anti-VEGF Treatment Strategy for Neovascular Age-Related Macular Degeneration: From Clinical Trials to Real-Life Requirements Irmela Mantel 1,2 1 Department
More informationRetinal Nerve Fiber Layer Thickness Changes in Patients with Age-Related Macular Degeneration Treated with Intravitreal Ranibizumab
Glaucoma Retinal Nerve Fiber Layer Thickness Changes in Patients with Age-Related Macular Degeneration Treated with Intravitreal Ranibizumab Jose M. Martinez-de-la-Casa, Aurora Ruiz-Calvo, Federico Saenz-Frances,
More informationOcular imaging in acquired retinopathy with multiple myeloma
Ocular imaging in acquired retinopathy with multiple myeloma ABDELRAHMAN GABER SALMAN MD- FRCS (GLASG)- MRCS (ED) ASSOCIATE PROFESSOR AIN SHAMS UNIVERSITY EVRS 2015 Immunogammopathies Immunogammopathies
More informationRisk factors of a reduced response to ranibizumab treatment for neovascular age-related macular degeneration evaluation in a clinical setting
Korb et al. BMC Ophthalmology 2013, 13:84 RESEARCH ARTICLE Open Access Risk factors of a reduced response to ranibizumab treatment for neovascular age-related macular degeneration evaluation in a clinical
More informationTHE ROLE OF anti-vegf IN DIABETIC RETINOPATHY AND AGE RELATED MACULAR DEGENERATION
THE ROLE OF anti-vegf IN DIABETIC RETINOPATHY AND AGE RELATED MACULAR DEGENERATION MOESTIDJAB DEPARTMENT OF OPHTHALMOLOGY SCHOOL OF MEDICINE AIRLANGGA UNIVERSITY DR SOETOMO HOSPITAL SURABAYA INTRODUCTION
More informationReview Article Spectral-Domain Optical Coherence Tomography for Macular Edema
Hindawi Publishing Corporation e Scientific World Journal Volume 2014, Article ID 191847, 6 pages http://dx.doi.org/10.1155/2014/191847 Review Article Spectral-Domain Optical Coherence Tomography for Macular
More informationBayer to showcase latest Ophthalmology research at EURETINA 2017
Investor News Not intended for U.S. and UK Media Bayer AG Investor Relations 51368 Leverkusen Germany www.investor.bayer.com 17 th European Society of Retina Specialists (EURETINA) Congress Bayer to showcase
More informationOphthalmology Macular Pathways
Ophthalmology Macular Pathways Age related Macular Degeneration Diabetic Macular Oedema Macular Oedema secondary to Central Retinal Macular Oedema secondary to Branch Retinal CNV associated with pathological
More informationThe Foundation WHAT IS THE RETINA?
Age-Related Macular Degeneration (AMD) is a deterioration of the retina and choroid that leads to a substantial loss in visual acuity (sharpness of vision). AMD is the leading cause of significant visual
More informationPART 1: GENERAL RETINAL ANATOMY
PART 1: GENERAL RETINAL ANATOMY General Anatomy At Ora Serrata At Optic Nerve Head Fundoscopic View Of Normal Retina What Is So Special About Diabetic Retinopathy? The WHO definition of blindness is
More informationClinical Study Effects of Intravitreal Ranibizumab Injection on Chinese Patients with Wet Age-Related Macular Degeneration: 5-Year Follow-Up Results
Ophthalmology Volume 2016, Article ID 6538192, 5 pages http://dx.doi.org/10.1155/2016/6538192 Clinical Study Effects of Intravitreal Ranibizumab Injection on Chinese Patients with Wet Age-Related Macular
More informationCENTRAL SEROUS CHORIORETINOPATHY (CSC) IS
Association Between the Efficacy of Half-Dose Photodynamic Therapy With Indocyanine Green Angiography and Optical Coherence Tomography Findings in the Treatment of Central Serous Chorioretinopathy MASSIMO
More informationGanglion cell complex scan in the early prediction of glaucoma
Original article in the early prediction of glaucoma Ganekal S Nayana Super Specialty Eye Hospital and Research Center, Davangere, Karnataka, India Abstract Objective: To compare the macular ganglion cell
More informationA view of the current and future role of optical coherence tomography in the management of age-related macular degeneration
(2017) 31, 26 44 2017 Macmillan Publishers Limited, part of Springer Nature. All rights reserved 0950-222X/17 www.nature.com/eye REVIEW A view of the current and future role of optical coherence tomography
More informationA retrospective nonrandomized study was conducted at 3
Department of Ophthalmology, Kangbuk Samsung Hospital, Sungkyunkwan University College of Medicine 1, Seoul, Korea Hangil Eye Hospital 2, Incheon, Korea Seoul National University Bundang Hospital 3, Seongnam,
More informationClinical Case Presentation. Branch Retinal Vein Occlusion. Sarita M. Registered Nurse Whangarei Base Hospital
Clinical Case Presentation on Branch Retinal Vein Occlusion Sarita M. Registered Nurse Whangarei Base Hospital Introduction Case Study Pathogenesis Clinical Features Investigations Treatment Follow-up
More informationYoshiro Minami 1*, Taiji Nagaoka 2, Akihiro Ishibazawa 1,2 and Akitoshi Yoshida 2
Minami et al. BMC Ophthalmology (2017) 17:90 DOI 10.1186/s12886-017-0485-4 RESEARCH ARTICLE Open Access Correlation between short- and long-term effects of intravitreal ranibizumab therapy on macular edema
More informationIQ 532 Micropulse Green Laser treatment for Refractory Chronic Central Serous Retinopathy
Cronicon OPEN ACCESS EC OPHTHALMOLOGY Case Report IQ 532 Micropulse Green Laser treatment for Refractory Chronic Central Serous Retinopathy Fawwaz Al Mamoori* Medical Retina Department, Eye Specialty Hospital,
More informationQuantitative Reduction in Central Foveal Thickness After First Anti-VEGF Injection as a Predictor of Final Outcome in BRVO Patients
Original clinical study Quantitative Reduction in Central Foveal Thickness After First Anti-VEGF Injection as a Predictor of Final Outcome in BRVO Patients Rupak Roy, MS, Kumar Saurabh, MS, Avirupa Ghose,
More informationWet AMD. dept headline headline. headline headline. From Start to Finish
Wet AMD dept headline headline From Start to Finish headline headline Deck Anti-VEGF therapy for patients with wet AMD is a standard of care that saves sight for thousands of people each year. dept byline
More informationClinical Study Choroidal Thickness in Eyes with Unilateral Ocular Ischemic Syndrome
Hindawi Publishing Corporation Journal of Ophthalmology Volume 215, Article ID 62372, 5 pages http://dx.doi.org/1.1155/215/62372 Clinical Study Choroidal Thickness in Eyes with Unilateral Ocular Ischemic
More informationGood News for The Macular Generation. Dr Andrew Thompson FRANZCO
Good News for The Macular Generation Dr Andrew Thompson FRANZCO Anti-VEGFs for wet MD are one of the greatest advances in medicine in past decade Prof. Gary Brown Director Wills Eye Institue Retina Service
More informationAn A to Z guide on Epiretinal Membranes (ERMs) Paris Tranos PhD,ICO,FRCS OPHTHALMICA Vitreoretinal & Uveitis Department
An A to Z guide on Epiretinal Membranes (ERMs) Paris Tranos PhD,ICO,FRCS OPHTHALMICA Vitreoretinal & Uveitis Department Types of ERM Natural history OCT prognostic factors ERM with co-existing pathology
More informationDiabetic Retinopathy: Recent Advances in Treatment and Treatment Approaches
Diabetic Retinopathy: Recent Advances in Treatment and Treatment Approaches Dr. David Wong Associate Professor Retina Specialist, Department of Ophthalmology & Vision Sciences, University of Toronto, Canada
More informationRetinal vein occlusion (RVO) is a vascular disease
INTRAVITREAL RANIBIZUMAB FOR RETINAL VEIN OCCLUSION THROUGH 1 YEAR IN CLINICAL PRACTICE TROELS BRYNSKOV, MD,* HENRIK KEMP, MD,* TORBEN L. SØRENSEN, MD, DMSC* Purpose: To evaluate the efficacy and safety
More informationEfficacy of intravitreal bevacizumab (Avastin TM ) for shortterm treatment of diabetic macular edema
111 ORIGINAL Efficacy of intravitreal bevacizumab (Avastin TM ) for shortterm treatment of diabetic macular edema Toshihiko Nagasawa, Takeshi Naito, Shingo Matsushita, Hiroyuki Sato, Takashi Katome, and
More informationDepartment of Ophthalmology, Kim s Eye Hospital, Konyang University College of Medicine, Seoul, Korea 2
pissn: 1011-8942 eissn: 2092-9382 Korean J Ophthalmol 2015;29(5):315-324 http://dx.doi.org/10.3341/kjo.2015.29.5.315 Original Article Clinical Outcomes of Eyes with Submacular Hemorrhage Secondary to Age-related
More informationFocal Macular Electroretinograms after Intravitreal Injections of Bevacizumab for Age-Related Macular Degeneration
Retina Focal Macular Electroretinograms after Intravitreal s of Bevacizumab for Age-Related Macular Degeneration Eiji Iwata, Shinji Ueno, Kohei Ishikawa, Yasuki Ito, Ruka Uetani, Chang-Hua Piao, Mineo
More informationFundus Autoflu ores cence Findings Pre and Post Intravitreal Bevacizumab Injection in Patients with Diabetic Macular Edema
Med. J. Cairo Univ., Vol. 84, No. 1, September: 1093-1100, 2016 www.medicaljournalofcairouniversity.net Fundus Autoflu ores cence Findings Pre and Post Intravitreal Bevacizumab Injection in Patients with
More information